BFM
IRD

Boothbay Fund Management’s Opus Genetics IRD Stock Holding History

Boothbay Fund Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.41M Buy
+1,189,113
New +$4.11M 0.07% 300
2022
Q2 		– Sell
-11,901
Closed -$39K – 2737
2022
Q1 		$39K Hold
11,901
– – ﹤0.01% 2201
2021
Q4 		$44K Hold
11,901
– – ﹤0.01% 1779
2021
Q3 		$61K Sell
11,901
-1,488
-11% -$6.86K ﹤0.01% 1833
2021
Q2 		$71K Hold
13,389
– – ﹤0.01% 1761
2021
Q1 		$78K Buy
+13,389
New +$124K ﹤0.01% 1485

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boothbay Fund Management's IRD Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in Opus Genetics (IRD) in Q1 2026: 1,189,113 shares worth $5.41M. The stake represents 0.07% of the portfolio and ranks #300 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in IRD as recently as Q1 2022.

Boothbay Fund Management first reported a position in IRD in Q1 2021 and has held it in 6 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Boothbay Fund Management held 1,189,113 shares of Opus Genetics worth $5.41M as of Q1 2026.
  • Opus Genetics was a new Boothbay Fund Management position in Q1 2026.
  • Opus Genetics made up 0.07% of Boothbay Fund Management's portfolio in Q1 2026, its #300 holding.
  • Boothbay Fund Management first reported a position in Opus Genetics in Q1 2021 and has held it in 6 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.